Pharma faces deadline to bring IRA fight to Supreme Court as first set of negotiated prices loomsnews2025-11-25T17:32:39+00:00November 25th, 2025|Endpoints News|
FDA approves Novartis’ Itvisma for older patients with spinal muscular atrophynews2025-11-25T12:09:26+00:00November 25th, 2025|Endpoints News|
Novartis was the sole bidder in $12B deal to buy Aviditynews2025-11-25T09:00:28+00:00November 25th, 2025|Endpoints News|
UK-US drug pricing deal could come as early as this week, sources saynews2025-11-24T20:53:12+00:00November 24th, 2025|Endpoints News|
J&J’s tau-targeting antibody fails Phase 2 Alzheimer’s studynews2025-11-24T16:22:48+00:00November 24th, 2025|Endpoints News|
Nobel laureate Carolyn Bertozzi to rejoin Lilly boardnews2025-11-24T09:15:20+00:00November 24th, 2025|Endpoints News|
Top Makary aide Jain-Nagpal remains at the FDA after White House pushbacknews2025-11-21T20:25:04+00:00November 21st, 2025|Endpoints News|
AstraZeneca to onshore rare disease portfolio as part of its $50B pledge to the USnews2025-11-21T19:33:41+00:00November 21st, 2025|Endpoints News|
Teva loses IRA drug pricing challenge in DC federal court news2025-11-21T19:19:47+00:00November 21st, 2025|Endpoints News|
FDA investigates child death potentially related to Takeda’s enzyme replacement therapynews2025-11-21T16:11:24+00:00November 21st, 2025|Endpoints News|
